Fig. 1 · Structure

Documents & Downloads

Mangiferin

Cat. No. A12088 CAS 4773-96-0
Mangiferin has been shown to have the effect of improving dyslipidemia.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
p65  
p50  
Nrf2  

Cellular Effect

Cell Line Activity Value Description Reference
BV-2 IC50 38.5 μM Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay [PMID: 24042007]
Vero CC50 > 500 μg/mL Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay [PMID: 31956052]
Vero IC50 2.9 μg/mL Antiviral activity against ACV-resistant Herpes simplex virus 1 AR-29 infected in African green monkey Vero cells assessed as inhibition of viral infection measured after 72 hrs by crystal violet staining based plaque reduction assay [PMID: 31956052]
Vero IC50 3.5 μg/mL Antiviral activity against ACV-sensitive Herpes simplex virus 1 KOS infected in African green monkey Vero cells assessed as inhibition of viral infection measured after 72 hrs by crystal violet staining based plaque reduction assay [PMID: 31956052]

Mangiferin Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Mangiferin from 3 published references. In vitro models include LNCaP cells; HNPCs.

Mangiferin In Vitro Studies

Mangiferin treatment produced no evident cytotoxicity in LNCaP cells under serum or serum-free conditions, as assessed by MTT assays. In HNPCs, Mangiferin treatment decreased intracellular ROS levels compared with the TNF-α group. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Mangiferin and LNCaP Cell Viability

Cell-based study · LNCaP cells [1]

LNCaP cells were treated with Mangiferin at up to 400 μM for 24 h. MTT assays showed no evident cytotoxicity under serum or serum-free conditions.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viability was measured using an MTT assayReported result There were no cytotoxic evident in LNCaP cells treated with up to 400 μM of mangiferin alone under both serum and serum-free conditions[1]

Literature-Reported Treatment Conditions

Treatment concentration
up to 400 μM
Exposure duration
24 h
Vehicle
DMSO (vehicle)
Reported limits
Not stated in the sentences used: route, control.
Methods and source locations

Compound reported in the paper: Mangiferin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

RESULTS > Effects of mangiferin on cell viability (S1, S2); MATERIALS AND METHODS > Reagent and antibodies (S23); MATERIALS AND METHODS > Cell culture and cell viability assay (S33); Fig. 1. legend (S77)

Cell viability was measured using an MTT assay: Cell viability was measured using an MTT assay — RESULTS > Effects of mangiferin on cell viability (S2); Fig. 1. legend (S77)

Mangiferin and Intracellular ROS in HNPCs

Cell-based study · HNPCs [2]

HNPCs were cultured with Mangiferin at 100 μM/ml or 500 μM/ml for 24 h. Intracellular ROS levels decreased by 80.52% and 91.66%, respectively, compared with the TNF-α group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
intracellular ROS levelsROS levels decreased by 80.52% and 91.66%, respectively[2]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM/ml; 500 μM/ml
Exposure duration
24 h
Method
cultured
Co-treatment
Other interventions in this design: TNF-α 20 ng/ml. Compound effect isolated by the comparison: compared with those in the TNF-α group.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Mangiferin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.14. ROS Assay (S71, S72, S74); 3. Results > 3.3. Mangiferin Alleviated TNF-α-Induced Oxidative Stress and Mitochondrial Dysfunction in HNPCs (S111, S120)

intracellular ROS levels: intracellular ROS levels; comparator: TNF-α group — 2. Materials and Methods > 2.14. ROS Assay (S72); 3. Results > 3.3. Mangiferin Alleviated TNF-α-Induced Oxidative Stress and Mitochondrial Dysfunction in HNPCs (S120)

Mangiferin In Vivo Studies

In the rat IVD needle puncture model, intradiscal injection of 0.2 μg of Mangiferin yielded higher MRI signal intensity than in the needle puncture group. In wild-type mice after LAD ligation, intraperitoneal Mangiferin at 40 mg/kg/day for 14 days resulted in significantly smaller infarct size than in mice without Mangiferin. [2,3]

Mangiferin and MRI Signal in Punctured Rat Intervertebral Discs

Animal study · Three-month-old Sprague-Dawley rats; rat IVD needle puncture model; n = 5 [2]

In a Sprague-Dawley rat IVD needle puncture model, Mangiferin was administered by intradiscal injection at 0.2 μg. MRI detected higher IVD signal intensity after Mangiferin treatment than in the needle puncture group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MRI-T2WIReported result 0.2 μg of mangiferin: MRI-T2WI detected a higher signal intensity in the rat IVD after mangiferin treatment than in the IVD of the needle puncture group.[2]

Conditions shared by the study groups

Route
intradiscal injection
Treatment course
intradiscal injection 3 days after puncture; Seven days after the initial puncture, X-ray and MRI scans before sacrifice
Vehicle
2 μl of PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Mangiferin 0.2 μgneedle puncture group0.2 μg of mangiferin: MRI-T2WI detected a higher signal intensity in the rat IVD after mangiferin treatment than in the IVD of the needle puncture group.[2]
Mangiferin 0.2 μg
Model: Three-month-old Sprague-Dawley rats; rat IVD needle puncture model; n = 5
Methods and source locations

Compound reported in the paper: Mangiferin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.5. Rats (S21, S24); 2. Materials and Methods > 2.8. X-Ray and Magnetic Resonance Imaging (MRI) Analyses (S40); 3. Results > 3.5. Mangiferin Alleviated the Degeneration of IVD in Rats In Vivo (S146, S148); Figure 5 legend (S210)

MRI-T2WI: MRI-T2WI; comparator: needle puncture group — 2. Materials and Methods > 2.5. Rats (S24); 3. Results > 3.5. Mangiferin Alleviated the Degeneration of IVD in Rats In Vivo (S148)

Mangiferin 0.2 μg · 2. Materials and Methods > 2.5. Rats (S24); 2. Materials and Methods > 2.8. X-Ray and Magnetic Resonance Imaging (MRI) Analyses (S40); 3. Results > 3.5. Mangiferin Alleviated the Degeneration of IVD in Rats In Vivo (S148)

Mangiferin and Infarct Size Following LAD Ligation

Animal study · wild‐type (C57BL/6) mice; n = 6 mice in each group [3]

Wild-type mice received Mangiferin by intraperitoneal injection at 40 mg/kg/day for 14 days after LAD ligation. Infarct size was significantly smaller in Mangiferin-treated mice than in mice without Mangiferin.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
infarct sizeReported result wild‐type (C57BL/6) mice; 40 mg/kg/day for 14 days after LAD ligation: the infarct size was significantly smaller in mangiferin‐treated mice.[3]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
for 14 days after LAD ligation
Vehicle
dimethyl sulfoxide (0.5% in phosphate‐buffered saline solution)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Mangiferin 40 mg/kg/daywithout mangiferinwild‐type (C57BL/6) mice; 40 mg/kg/day for 14 days after LAD ligation: the infarct size was significantly smaller in mangiferin‐treated mice.[3]
Mangiferin 40 mg/kg/day
Model: wild‐type (C57BL/6) mice; n = 6 mice in each group
Methods and source locations

Compound reported in the paper: Mangiferin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

MATERIALS AND METHODS > Infarction model, drug treatment, measurement of the infarct size and survival rate (S18); RESULTS > Mangiferin alleviates MI‐induced cardiomyocyte apoptosis and heart failure (S75, S76); FIGURE 1 legend (S123, S129)

infarct size: infarct size; comparator: without mangiferin — MATERIALS AND METHODS > Infarction model, drug treatment, measurement of the infarct size and survival rate (S18); RESULTS > Mangiferin alleviates MI‐induced cardiomyocyte apoptosis and heart failure (S75, S76)

Mangiferin 40 mg/kg/day · MATERIALS AND METHODS > Infarction model, drug treatment, measurement of the infarct size and survival rate (S18); RESULTS > Mangiferin alleviates MI‐induced cardiomyocyte apoptosis and heart failure (S75, S76)

Specifications

Manufacturer Adooq Bioscience
CAS Number 4773-96-0
Formula C19H18O11
Molecular Weight 422.33
Synonyms Alpizarine
SMILES
C1=C2C(=CC(=C1O)O)OC3=CC(=C(C(=C3C2=O)O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 79 mg/mL (187.05 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Mangiferin Research References

  1. [1] Dilshara MG, Kang CH, Choi YH, et al. Mangiferin inhibits tumor necrosis factor-α-induced matrix metalloproteinase-9 expression and cellular invasion by suppressing nuclear factor-κB activity. BMB Rep (2015). PMID: 25739392 DOI: 10.5483/bmbrep.2015.48.10.003 Source material
  2. [2] Yu H, Hou G, Cao J, et al. Mangiferin Alleviates Mitochondrial ROS in Nucleus Pulposus Cells and Protects against Intervertebral Disc Degeneration via Suppression of NF-κB Signaling Pathway. Oxid Med Cell Longev (2021). PMID: 34234886 DOI: 10.1155/2021/6632786 Source material
  3. [3] Chen L, Li S, Zhu J, et al. Mangiferin prevents myocardial infarction-induced apoptosis and heart failure in mice by activating the Sirt1/FoxO3a pathway. J Cell Mol Med (2021). PMID: 33523605 DOI: 10.1111/jcmm.16329 Source material

Added to your cart

View Cart Checkout
Loading...